The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could ...

(Bloomberg) -- Novo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a kidney-disease study, the latest research pointing to the medicine’s usefulness in a ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Ozempic is already approved to treat T2D, for cardiovascular risk reduction ... worsening kidney disease and cardiovascular death in people with T2D and CKD. …as Rybelsus cuts MACE in type ...

Share on Pinterest Recent anecdotal reports have highlighted strange side effects of GLP-1 medications used for weight loss like “Ozempic ... health lowering kidney disease risk improving ...

The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taking semaglutide stopped their fatty ...

International study looked at 800 patients in 37 countries Patients getting the drug saw less inflammation and fat in their livers Lead researcher says it could help treat liver disease like MASH ...